Thus, our results are rather limited to a specific type of leukemia and our data imply that SK/IK channel inhibitors could be used to slow down the proliferation and spreading of CML K562 cells that express functionally active SK2, SK3 and IK channels in the plasma membrane. The gene discussed is KCNN2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.